PubMed Health⌕ Search

Biomedical subjects

Jacques Irani

Publications and source records attributed to Jacques Irani.

At least 19 recordsLinked to original sources
PubMed2006

Effect of dutasteride on the symptoms of benign prostatic hyperplasia, and patient quality of life and discomfort, in clinical practice.

OBJECTIVE: To assess the improvements in symptoms, quality of life (QoL), discomfort and satisfaction in patients with symptomatic benign prostatic hyperplasia (BPH) treated with dutasteride in clinical practice. PATIENTS AND METHODS: In a prospective, multicentre open-label study, we evaluated the efficacy and safety in clinical practice of dutasteride, 0.5 mg/day for 24 weeks, in patients with symptomatic BPH. The primary endpoint was the proportion of patients achieving at least a 3-point decrease from baseline in the International Prostate Symptom Score (IPSS) after 24 weeks of treatment. The secondary endpoints included changes from baseline in measures of QoL (IPSS item 8 and BPH Impact Index score, BII), and patient discomfort and satisfaction (visual analogue scales, VAS) at 12 and 24 weeks. RESULTS: Of the 366 patients assessed, 72.5% achieved at least a 3-point reduction in IPSS at 24 weeks; the IPSS decreased from 15.3 at baseline to 10.2 at 12 weeks, and to 9.1 at 24 weeks. There were significant (P < 0.001) decreases in all the individual IPSS items at 12 and 24 weeks, with more marked improvements in voiding symptoms than storage symptoms. There were also significant (P < 0.001) improvements in the BII and VAS scores for patient discomfort and satisfaction at both times. CONCLUSIONS: Dutasteride treatment for 24 weeks significantly improved BPH symptoms, QoL and patient discomfort and satisfaction, and was well tolerated in clinical practice.

Azasteroids↗
PubMed2006

[Does the initial or secondary status of T1G3 bladder tumours have a prognostic impact?].

OBJECTIVE: This retrospective study evaluated the prognostic value of the initial or secondary status of pT1G3 bladder tumours. MATERIALS AND METHODS: Between 1990 and 2000, 93 patients presented with T1G3 bladder tumour. Seventy-five patients, 54 with initial T1G3 and 21 with secondary T1G3, with no history of invasive bladder tumour, were included in the study. Seventy-two per cent were treated by intravesical BCG. No patient received maintenance therapy. The median follow-up was 53 months (range: 2 to 285 months). RESULTS: On univariate analysis, a significant difference of overall survival was observed in favour of secondary T1G3 tumours compared to initial T1G3 tumours (p < 0.003), while no difference was observed for recurrence, progression and specific survival. This difference was no longer significant on multivariate analysis, but BCG therapy and smoking were significantly correlated with overall and specific mortality. BCG was also correlated with risk of progression. CONCLUSION: Patients with a secondary T1G3 tumour had a better overall survival. This difference was no longer significant when other prognostic factors were taken into account.

Aged↗
PubMed2006

[Macroscopic haematuria after transurethral resection of the prostate].

UNLABELLED: Although macroscopic haematuria during the month following transurethral resection of the prostate, due to sloughing of necrotic tissue, is a phenomenon well known to urologists since introduction of endoscopic resection, its pathophysiological and epidemiological characteristics are poorly defined. The objective of this retrospective study was to define the incidence of serious macroscopic haematuria after transurethral resection of the prostate (TURP) and to identify the risk factors for macroscopic haematuria. PATIENTS AND METHODS: The hospital database was used to identify patients treated by TURP between 1997 and 2004 and rehospitalized during the 31 days following the procedure. Files of patients presenting with haematuria and bladder clots were selected and analysed. RESULTS: Ten of a series of 624 patients undergoing TURP were hospitalised for bladder clots and their case files were analysed: median age: 72 years, median duration of TURP: 45 min and median weight of resection: 12 g. The operators' experience and the duration of post-TURP catheterization were not informative. In 2 cases, prostate cancer was diagnosed after analysis of resection chips. Two patients were treated by anticoagulants. Patients were essentially rehospitalized during the 2nd week (median: 11th day). A bladder catheter for was inserted for lavage in each case. No patient required reoperation or removal of clots under general anaesthesia. Two patients were transfused. CONCLUSION: We did not identify any risk factor for sloughing leading to macroscopic haematuria during the month following TURP. Macroscopic haematuria justifying rehospitalization is a rare event. However, in view of this low incidence, optimal analysis could only be performed in the context of a national prospective register.

Aged↗
PubMed2005

The role of luteinizing hormone-releasing hormone therapy in locally advanced prostate cancer and biochemical failure: considerations for optimal use.

BACKGROUND: More patients are being diagnosed with prostate cancer at an earlier age with earlier stage disease because of advances in screening and detection. Investigators continue to explore the use of hormone therapy, particularly luteinizing hormone-releasing hormone (LHRH) analogues, earlier in the course of disease. OBJECTIVE: This review summarizes clinical evidence regarding the safety and efficacy of LHRH analogues in the treatment of locoregional disease or following biochemical failure. METHODS: Relevant information from clinical studies was identified through a MEDLINE search of the medical literature published in English in the last 5 years (search terms: LHRH and prostate cancer). The search included prospective and retrospective clinical studies on LHRH therapy in locally advanced prostate cancer. Additional relevant publications published before 1999 were identified from citations in the resulting articles. RESULTS: The available clinical evidence suggests that the use of LHRH analogues as adjuvant or neoadjuvant therapy in conjunction with radiation therapy may improve survival outcomes. Few studies have evaluated the use of LHRH analogues after biochemical failure. However, several related studies indicate that initiating hormone therapy earlier rather than later may provide some clinical benefit. When considering early initiation of LHRH therapy, the potential risks of long-term treatment must be considered. Physiologic changes, such as deterioration of body composition and bone quality, may have important effects on the risk of developing cardiovascular disease and osteoporosis. CONCLUSIONS: Although some clinical evidence supports the use of LHRH analogues as adjuvant or neoadjuvant therapy or following biochemical failure, further study is needed. In the meantime, clinicians should carefully weigh the potential benefits and risks of early hormone therapy when making treatment decisions.

Chemotherapy, Adjuvant↗
PubMed2005

Urinary/serum prostate-specific antigen ratio: comparison with free/total serum prostate-specific antigen ratio in improving prostate cancer detection.

OBJECTIVES: To test the previously reported hypothesis, that the urinary/total serum (U/S) prostate-specific antigen (PSA) ratio improves the detection of prostate cancer, by evaluating the clinical usefulness of the U/S PSA ratio and comparing it with the free/total (F/T) serum PSA ratio. METHODS: A total of 165 patients undergoing transrectal ultrasound-guided prostate biopsy were prospectively included in this multicenter study. In all patients, PSA was measured from preoperative serum and 12-hour urine specimens in a centralized laboratory. RESULTS: Prostate cancer was identified in 83 of 165 patients. The differences between patients with and without prostate cancer were statistically significant (P <0.001) when considering the total PSA value (median, 10.2 ng/mL and 6.6 ng/mL respectively), F/T serum PSA ratio (0.11 and 0.18), and U/S PSA ratio (1.2 and 4.2). In the group of 79 patients with a PSA level between 4 and 10 ng/mL, receiver operating characteristic curves showed that the U/S PSA ratio was associated with a larger area under the curve (0.63; 95% confidence interval, 0.51 to 0.73) than the total PSA value (0.55; 95% confidence interval, 0.43 to 0.66) or F/T serum PSA ratio (0.60; 95% confidence interval, 0.49 to 0.71). The U/S PSA ratio did not correlate with patient age or prostate volume. CONCLUSIONS: Our results confirmed that the U/S PSA ratio may be a useful test in prostate cancer detection when the total serum PSA level is between 4 and 10 ng/mL. The F/T serum PSA ratio and U/S PSA ratio did not correlate. This suggests that these two tests could complement each other.

Aged↗
PubMed2005

[A striking image].

Explore the source record for details and available documents.

Disease-Free Survival↗
PubMed2005

[Follow-up of urothelial tumours. Guidelines of the Comité de Cancérologie de l'Association Française d'Urologie].

The follow-up of urothelial tumours is designed to allow early detection of recurrence or progression, for which treatment is possible. Recent interesting points are: the more frequent and simpler use of the new classification into low grade and high grade, essentially applied to the management and surveillance of tumours involving the mucosa or lamina propria; and the limited place of urinary markers.

Carcinoma, Transitional Cell↗
PubMed2004

[International comparison of guidelines for the management of benign prostatic hyperplasia: use of a validated generic tool].

INTRODUCTION: Many clinical practice guidelines (CPG) have been developed over the last decade for the management of benign prostatic hyperplasia (BPH) and associated lower urinary tract disorders. The purpose of this study was to analyse CPG published on the web until the end of 2001 and to compare their content and their methodology of development by using a validated evaluation tool. methodologies of development of CPG and their content using a validated tool. RESULTS: The methodology of elaboration and presentation of CPG was insufficient in the majority of CPGs. The type and number of diagnostic examinations recommended by each CPG were very variable. A consensus concerning treatment was reached at the cost of poorly defined criteria, apart from complications of BPH. CONCLUSION: The considerable number of men potentially eligible for management of voiding disorders related to BPH in the years to come will constitute a substantial medico-economic burden. Consensual rationalisation of this management by urologists in order to ensure practical application of the guidelines would limit expenditure without decreasing the quality of patient management. However, our study showed limited coherence between the various CPG, suggesting that rationalisation should first be applied to the method of development of CPG.

Humans↗
PubMed2004

[Long-term follow-up of 88 patients operated for primary vesicorenal reflux in childhood].

OBJECTIVE: To determine the long-term outcome of patients operated for primary vesicorenal reflux (VRR) in childhood. MATERIALS AND METHOD: This study concerned 88 patients successfully operated for VRR in childhood before 1986 and who answered a questionnaire in 2001. The medical files were reviewed retrospectively and reflux was re-evaluated according to the latest international classification. RESULTS: The median follow-up was 21.5 years [range: 15-27]. The mean age at the time of diagnosis was 5.5 years. In 92% of cases, reflux presented in the form of acute pyelonephritis (APN). 88.5% of the patients contacted declared that they were in good general health and 15.4% of males and 50.6% of females presented episodes of cystitis. However, only 16% of females and no males reported episodes of APN. The presence of renal lesions did not statistically increase the risk of febrile urinary tract infection. No case of APN occurred during the 37 pregnancies reported. One female patient suffered from renal failure due to an aetiology unrelated to reflux. One female patient with a scarred kidney before the operation presented hypertension. CONCLUSION: This study shows that the outcome of patients operated for primary VRR in childhood is favourable despite the persistence of APN. The increasingly early surgical management of VRR will certainly be optimized by long-term follow-up studies with initial assessment of the lesions based on scintigraphic techniques.

Child, Preschool↗